Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Merrimack Pharma

How published research underpinned a cancer therapy awareness campaign

Our client markets a product for Oral Mucositis (OM) - a side effect of cancer treatment - and wanted to better understand the disease and treatment challenges faced by both...

Research Partnership

How a hybrid approach delivered fast insights to feed into an oncology product’s adoption strategy

Our client wanted to quantify how ovarian cancer patients are managed prior to product launch, but also needed to understand why patients do or do not receive key diagnostic tests...

Research Partnership

Oncology experience & expertise

Did you know 25% of our business is in Oncology?

Research Partnership

Sanofi reception

Sanofi’s latecomer PD-1 gets date for FDA verdict

While Keytruda extends its lead, Sanofi makes a late bid to enter PD-1 space

- PMLiVE

Rigel and Ultragenyx claim approvals for rare drugs

Tavalisse and Crysvita are set to treat patients with chronic ITP and XLH, respectively

Bristol-Myers Squibb (BMS) building

BMS claims rapid FDA nod for Opdivo plus Yervoy in kidney cancer

Data shows the combo can improve survival compared to Pfizer’s Sutent

- PMLiVE

Shire offloads oncology unit to Servier for $2.4bn

The French drugmaker will also acquire Oncaspar and Onivyde as part of the deal

- PMLiVE

Beyond caring: learning from the unsung advocates in cancer care

Macmillan Cancer Support estimates that there are currently around 1.5 million carers caring for someone who has cancer in the UK. Broadly, carers in and outside cancer contribute around £132...

- PMLiVE

Ipsen bolsters leadership team

Ivana Magovcevic-Liebisch and Régis Mulot join the biopharma

- PMLiVE

Alkermes slumps as FDA turns down depression drug

The drug needs to be supported with additional trials and a bioavailability study, says US regulator

How scenario testing helped assess demand for a brand launch in the fragmented NSCLC market

Our client was developing a new drug aimed at first line NSCLC patients. Ahead of its launch they wanted to assess likely uptake in an already fragmented market space led...

Research Partnership

- PMLiVE

Health on instalment

Can US-style financial engineering underwrite ultra-expensive gene therapies?

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links